Study of combination therapy with SYR-322

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221694

Enrollment

179

Registered

2012-01-20

Start date

2012-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes mellitus

Interventions

investigational material(s) Generic name etc : SYR-322 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : 2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The subject is an outpatient. 2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

Exclusion criteria: 1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease. 2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026